title: Chemical ligands, genomics and drug discovery.
abstract: The sequencing of the human genome and numerous pathogen genomes has resulted in an explosion of potential drug targets. These targets represent both an unprecedented opportunity and a technological challenge for the pharmaceutical industry. A new strategy is required to initiate small-molecule drug discovery with sets of incompletely characterized, disease-associated proteins. One such strategy is the early application of combinatorial chemistry and other technologies to the discovery of bioactive small-molecule ligands that act on candidate drug targets. Therapeutically active ligands serve to concurrently validate a target and provide lead structures for downstream drug development, thereby accelerating the drug discovery process.
authors.affiliation: NeoGenesis, 840 Memorial Drive, Cambridge, MA 02139, USA.
authors.initials: GR
authors.lastname: Lenz
authors.initials: HM
authors.lastname: Nash
authors.initials: S
authors.lastname: Jindal